

Immunodiagnostic Determination Of Usher Syndrome Type IIa

Abstract of the Disclosure

5 Methods and test kits for determining whether an individual has or is at risk
for developing Usher syndrome Type IIa. The methods include obtaining a
biological sample from an individual, incubating the biological sample with at least
one antibody which is immunoreactive with an USH2a protein under conditions
effective to produce immunoconjugates if the usherin protein is present, evaluating
10 for the presence or absence of immunoconjugates, and correlating the presence of
immunoconjugates with the individual not having Usher syndrome Type IIa, and the
absence of immunoconjugates with the individual having or being at risk for
developing Usher syndrome Type IIa.

“EXPRESS MAIL” MAILING LABEL NUMBER: EL 288 271 064 US
DATE OF DEPOSIT: 03 OCTOBER 2001
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE
UNITED STATES POSTAL SERVICE “EXPRESS MAIL POST OFFICE TO ADDRESSEE”
SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231
PRINTED NAME: GARA L. LADWIG
SIGNATURE: Gara L. Ladwig